RxDoctor Payments Data

Michael Conte, MD

Vascular Surgery · San Francisco, CANPI 1417993247

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.2%. Reporting peaked in 2024 at $8,389 and has fallen 55.2% since, to $3,755 in 2025.

$29,035in general payments, 2019–2025

Across 83 payments — averaging $349.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$7K
  • Pfizer$6K
  • Abbott$6K
  • Boston Scientific$4K
  • Janssen Scientific Affairs, LLC$3K
  • W. L. Gore & Associates, Inc.$1K
  • plus $3K from 15 others
$79,922in research payments, 2019–2025

Across 13 payments — averaging $6147.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medistim USA, Inc.$47K
  • Boston Scientific$17K
  • Inari Medical, Inc.$16K

What the payments were for

  • Consulting fees$16,53557%
  • Speaking & faculty fees$4,50015%
  • Travel & lodging$2,2398%
  • Food & beverage$5,76120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,035 in reported general payments places this provider in the 85th percentile of 519 vascular surgery providers in California.

See all vascular surgery providers in California

Medicare billing

Part B allowed, 2024
$114,142
Medicare patients
582
Services billed
994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate14$31

Paid to pharmacies, not to this prescriber.

Other vascular surgery in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →